This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Navalkar, S. Articles by Khan, B. V. Search for Related Content PubMed PubMed Citation Articles by Navalkar, S. Articles by Khan, B. V.

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

Sushant Navalkar, MD^*, Sampath Parthasarathy, PhD, Nalini Santanam, PhD and Bobby V. Khan, MD, PhD^*

^* Department of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA
Gynecology/Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA

View larger version (17K): [in a new window]   Figure 1 Patients with premature CAD were placed on a daily dose of irbesartan (75 mg daily if systolic blood pressure 135 mm Hg and 150 mg daily if systolic blood pressure 135 mm Hg) for a 24-week period. Blood pressure was monitored at 0, 4, 12 and 24-week intervals. The average systolic and diastolic blood pressure for the group at each interval is noted. = systolic; = diastolic.

View larger version (16K): [in a new window]   Figure 2 Serum levels of soluble VCAM-1 (ng/dl) were measured in subjects with known coronary artery disease (CAD) by enzyme-linked immunosorbent assay technique. Diamonds represent the change in sVCAM-1 levels over the 24-week study period at intervals of 0, 4, 12 and 24 weeks in patients with CAD treated with irbesartan. Squares represent sVCAM-1 levels measured in control patients over the study period at the same interval schedule. Values for CAD patient group represent mean ± SD. * = value differs (p < 0.001) from the control group. # = value differs (p < 0.001) from the CAD group before treatment with irbesartan. = CAD; = control.

View larger version (14K): [in a new window]   Figure 3 Serum levels of TNF-RII (ng/dl) were measured in subjects with known coronary artery disease (CAD) by enzyme-linked immunosorbent assay technique. Diamonds represent the change in TNF-RII levels over the 24-week study period at intervals of 0, 4, 12 and 24 weeks in patients with CAD treated with irbesartan. Squares represent TNF-RII levels measured in control patients over the study period at the same interval schedule. Values for CAD patient group represent mean ± SD. * = value differs (p < 0.001) from the control group. # = value differs (p < 0.001) from the CAD group before treatment with irbesartan. = CAD; = control.

View larger version (16K): [in a new window]   Figure 4 Serum levels of superoxide (ng/mg) were measured in subjects with known coronary artery disease (CAD) by the lucigenin chemiluminescence assay. Diamonds represent the change in TNF-RII levels over the 24-week study period at intervals of 0, 4, 12 and 24 weeks in patients with CAD treated with irbesartan. Squares represent superoxide levels measured in control patients over the study period at the same interval schedule. Values for CAD patient group represent mean ± SD. * = value differs (p < 0.01) from the control group. # = value differs (p < 0.01) from the CAD group before treatment with irbesartan. = CAD; = control.